A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy

A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy

Despite advances in ovarian cancer (OC) therapy, recurrent OC remains a poor-prognosis disease. Because of the close interaction between OC cells and the tumor microenvironment (TME), it is important to develop strategies that target tumor cells and engage components of the TME. A major obstacle in...

Full description

Bibliographic Details
Main Authors: Devivasha Bordoloi, Pratik S. Bhojnagarwala, Alfredo Perales-Puchalt, Abhijeet J. Kulkarni, Xizhou Zhu, Kevin Liaw, Ryan P. O’Connell, Daniel H. Park, Daniel W. Kulp, Rugang Zhang, David B. Weiner
Format: Article
Language:English
Published: American Society for Clinical investigation 2022-11-01
Series:JCI Insight
Subjects:
Oncology
Therapeutics
Online Access:https://doi.org/10.1172/jci.insight.162553

Internet

https://doi.org/10.1172/jci.insight.162553

Similar Items